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ABSTRACT
The menopause transition (MT) may be an opportunity for early intervention to prevent rapid bone loss. To intervene early, we need
to be able to prospectively identify pre- and perimenopausal women who are beginning to lose bone. This study examined whether
estradiol (E2), or follicle-stimulating hormone (FSH), measured in pre- and perimenopausal women, can predict significant bone loss
by the next year. Bone loss was considered significant if bone mineral density (BMD) decline at the lumbar spine (LS) or femoral neck
(FN) from a pre- or early perimenopausal baseline to 1 year after the E2 or FSH measurement was greater than the least detectable
change. We used data from 1559 participants in the Study of Women’s Health Across the Nation and tested E2 and FSH as separate
predictors using repeated measures modified Poisson regression. Adjusted for MT stage, age, race/ethnicity, and body mass index,
women with lower E2 (and higher FSH) were more likely to lose BMD: At the LS, each halving of E2 and each doubling of FSH were
associated with 10% and 39% greater risk of significant bone loss, respectively (p < 0.0001 for each). At the FN, each halving of E2 and
each doubling of FSH were associated with 12% (p = 0.01) and 27% (p < 0.001) greater risk of significant bone loss. FSH was more
informative than E2 (assessed by the area under the receiver-operator curve) at identifying women who were more versus less likely
to begin losing bone, especially at the LS. Prediction was better when hormones were measured in pre- or early perimenopause than
in late perimenopause. Tracking within-individual change in either hormone did not predict onset of bone loss better than a single
measure. We conclude that measuring FSH in the MT can help prospectively identify women with imminent or ongoing bone loss at
the LS. © 2019 American Society for Bone and Mineral Research.
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Introduction
The menopause transition (MT) is a period of rapid bone lossthat contributes to a woman’s risk of osteoporosis and frac-
ture in later life. Bone mineral density (BMD) decline, at rates
commonly observed during the MT,(1) can be associated with
irreversible deterioration in bone microarchitecture(2–4) and with
increased fracture risk.(5–7) Indeed, in some studies, fast BMD
decline in midlife is associated with appendicular and vertebral
fractures within the first postmenopausal decade.(8–10) This sug-
gests that theMTmay be an opportune time for early, short-term
intervention to prevent rapid BMD decline and reduce the risk of
future fracture.(11)
To intervene before substantial bone loss has occurred, we
first need to be able to predict whether a pre- or perimenopausal
woman is about to begin losing bone. MT-related BMD decline
accelerates approximately 1 year before the final menstrual
period (FMP).(1) Currently, however, this time point can only be
identified retrospectively, ie, after ≥12 months of amenorrhea
when the FMP date can be assigned.(12) By the time the FMP date
can be defined, many womenwill have already been losing bone
for the preceding 2 years. Becasue the rate of BMD decline at the
lumbar spine during the MT averages 2.5% per year,(1) even a rel-
atively short period of bone loss can be significant. The objective
of this study was, therefore, to determine whether markers of
ovarian function—estradiol (E2) or follicle-stimulating hormone
(FSH)—measured in pre- and perimenopause can help prospec-
tively identify the onset of significant bone loss in advance of
substantial BMD decline.
E2 is the major sex steroid hormone in women, and the likely
effector estrogen at the estrogen receptor.(13,14) FSH is produced
by the anterior pituitary under negative feedback inhibition by
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estrogen. We considered E2 and FSH as potential predictors of
imminent BMD decline because an increase in FSH and decrease
in E2 temporally precedes the MT-related acceleration in bone
loss.(1,15–17) We thus designed this study to address two ques-
tions: 1) Can measuring E2 or FSH during pre- (regular menstrual
bleeding), early peri- (less predictable bleeding at least once
every 3 months), or late perimenopause (less predictable bleed-
ing at least once every 3 to 12 months) help determine if a
womanwill have significant decline in BMD (from an earlier base-
line) by the next 12 months; and 2) Does tracking within-
individual change in E2 or FSH improve this determination?
This study was conducted in the Study of Women’s Health
Across the Nation (SWAN), a longitudinal cohort study of the
MT in a multi-ethnic, community-based cohort of women with
annual measurements of E2, FSH, and BMD.
Materials and Methods
SWAN is amulticenter, longitudinal study of theMT in amultiracia-
l/ethnic cohort of ambulatory, community-dwelling women.(18)
SWAN was initiated in 1996, when participants were aged 42 to
52, and in pre- (no change in menstrual bleeding in the past year)
or early perimenopause (less predictable menstrual bleeding at
least once every 1 to 3 months in the past year). A total of 3302
SWAN participants were recruited at seven clinical sites: Boston,
MA; Chicago, IL; Detroit, MI; Pittsburgh, PA; Los Angeles, CA; New-
ark, NJ; and Oakland CA. The SWAN Bone Cohort includes 2417
participants from five sites (excluding the Chicago and Newark
sites). Among these women, E2, FSH, and BMD were measured at
baseline and at each follow-up visit thereafter. Each clinical site
obtained IRB approval, and all participants provided written
informed consent.
Study sample
Of 2417 SWAN bone cohort participants, 336 women were
excluded because they did not have at least two measurements
(at baseline visit and at least one follow-up visit) of E2 or FSH.
The most common reason for exclusion was starting a bone-
modifying medication (including sex steroid hormones, oral
glucocorticoids, aromatase inhibitors, chemotherapy for breast
cancer, and osteoporosis medications [bisphosphonates, selec-
tive estrogen receptor modulators, calcitonin, parathyroid hor-
mone]) before the second E2 or FSH measurement. Of the
remaining participants, another 507 women were excluded
because their first E2 or FSHmeasurement was not obtained dur-
ing the early follicular phase (days 2 to 5) of the menstrual cycle.
We lastly excluded 15 women who did not have at least one
follow-up visit before postmenopause (defined as ≥1 year after
the FMP), around which we could determine whether significant
bone loss occurred. We could not assess for BMD loss if there
was missing baseline or follow-up BMD data, or if a bone-
modifying medication was initiated before the second dual-
energy X-ray absorptiometry (DXA) scan. Our analytic sample
was thus 1559 women (Fig. 1). Among these participants, a total
of 3618 follow-up visits starting from the first follow-up visit to
the last visit before the clinical diagnosis of postmenopause could
be made were included in our analyses.
Predictors
Every effort was made to perform phlebotomy before 10:00 a.m.
during the early follicular phase (between days 2 and 5) of a
spontaneous menstrual cycle. If a follicular phase sample could
not be obtained after two attempts, a random fasting sample
was taken within a 90-day window of the anniversary of the
baseline visit. Collected specimens were initially stored between
−20C and −80C at individual study sites for up to 30 days and
then shipped to the Central Lab at the University of Michigan
(Ann Arbor, MI, USA), and stored at−80C. Assays were then per-
formed in batchmode. Serum E2wasmeasured in duplicate with
a modified, offline ACS:180 (E2–6) immunoassay using an
ACS:180 automated analyzer (Bayer Diagnostics Corp., Tarry-
town, NY, USA). The average between duplicates was recorded
in the data set and used in the analyses in this study. The lower
limit of detection was 1.0 pg/mL, and inter- and intraassay coef-
ficients of variation (CV) were 10.6% and 6.4%, respectively.
Serum FSH was measured in singlicate with a 2-site chemilumi-
nometric assay (Bayer Diagnostics Corp.). The lower limit of
detection was 1.05 mIU/mL, and inter- and intraassay CV were
12.0% and 6.0%, respectively.
Outcomes
BMD at the lumbar spine (LS) and femoral neck (FN) BMD was
measured by DXA. At study inception, the Pittsburgh and
Fig. 1. Analysis sample derivation. This flow chart shows the derivation
of the analysis sample. To be included in the study, participants needed
to meet the following criteria: 1) be from a SWAN bone site; 2) have at
least two E2 or FSHmeasurements, the first of whichwas obtained during
the early follicular phase (EFP) of the menstrual cycle; and 3) have at least
one follow-up visit before postmenopause, around which significant
bone loss could be assessed.
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Oakland sites used the Hologic (Waltham, MA, USA) QDR 2000
machine, and the Boston, Los Angeles, and Michigan sites used
the Hologic QDR 4500A model. At follow-up visit 8, Pittsburgh
and Oakland upgraded to the 4500A models. To develop cross-
calibration regression equations, each site obtained duplicate
scans using the old and new hardware in 40 volunteers within a
maximum of 90 days. Of the 3618 observations included in our
analyses, only 56 occurred after the machine changes. To deter-
mine the short-term in vivo precision error, each study site mea-
sured LS and FN BMD twice in 5 women with complete subject
repositioning between duplicate scans. Using the root mean
square SD approach, the precision error in SWAN was 1.4% at
the LS and 2.2% at the FN. An anthropomorphic spine phantom
was circulated between sites for cross-site calibration. Standard
quality-control phantom scans were conducted before each
BMD measurement session. If necessary, these were used to
adjust for longitudinal machine drift.
For each follow-up visit N, we calculated the percentage
decline in LS and FN BMD from SWAN baseline to follow-up visit
N + 1. Significant BMD decline was defined as loss of BMD that
exceeded the site-specific least significant change (LSC). LSC is
the amount of change that is considered statistically significant
using a two-sided type I error (alpha) of 5%, given the measure’s
precision error (coefficient of variation [CV]). The LSC (which is 2.8
times the measurement’s CV) is thus 3.9% for LS BMD and 6.2%
for FN BMD.
Covariates
Body mass index (BMI) was calculated from weight and height
measurements (BMI = weight in kilograms/[height in meters]2).
Clinical MT stage was determined using menstrual bleeding pat-
terns. Premenopause was defined as no change in menstrual
regularity in the past year. Early perimenopause was defined as
less predictable menstrual bleeding at least once every
3 months. Late perimenopause was defined as less predictable
menstrual bleeding at least once every 3 to 12 months.
Statistical analysis
We generated descriptive statistics for all variables and assessed
the distributions of continuous variables. E2 and FSH had skewed
distributions and were thus log transformed to base 2 for all
analyses.
In our first set of analyses, we assessed whether a one-time
measurement of E2 or FSH could predict imminent bone loss
by the next year. We used repeated measures, modified Poisson
regression with E2 or FSH measured at each follow-up visit N as
primary predictor, and significant bone loss (yes versus no) at
the LS or FN from SWAN baseline to follow-up visit N + 1 (yes/no)
as the dependent variable (Fig. 2A). E2 and FSH were tested in
separate models. Models were adjusted for MT stage (pre- versus
early peri- versus late perimenopause) and relevant clinical cov-
ariates (age, race/ethnicity, BMI, SWAN study site, and whether
follow-up E2 or FSH more measured during the early follicular
phase of the menstrual cycle).
In our second set of analyses, we examined the ability of
within-individual change in E2 or FSH to predict imminent bone
loss by the next year of the second hormone measurement. We
again used repeated measures, modified Poisson regression, this
time with change in log-transformed E2 or FSH from SWAN base-
line to each follow-up visit N as primary predictor, and significant
bone loss at the LS or FN from SWAN baseline to follow-up visit
N + 1 (yes/no) as dependent variable (Fig. 2B). Models were
adjusted for MT stage, and relevant clinical covariates as above.
Time-varying covariates were obtained at the time of the second
hormone measurement.
In both sets of analyses, we compared the abilities of E2 and
FSH to discriminate womenwhoweremore likely from those less
likely to be losing bone, using the area under the receiver oper-
ating characteristic curve (AUC) metric (estimated using logistic
regression).(19) We also tested for interactions of each hormone
with race/ethnicity, MT stage, and whether the hormone was
measured during the early follicular phase (EFP, days 2 to 5) of
the menstrual cycle to see if the strength of each hormone’s
association (effect size) differed by those factors.
Lastly we conducted three sets of sensitivity analyses. First, we
examined whether excess weight loss or weight gain affected
the associations of E2 and FSH with significant bone loss. Specif-
ically, we excluded observations for which change in weight
from the baseline visit to the exposure visit was in the bottom
5% or top 5% of the population distribution (ie, weight loss
>5.8 kg or weight gain >9.2 kg). Second, the SWAN protocol for
cross-calibration after a DXA hardware change did not meet
the International Society for Clinical Densitometry’s (ISCD’s) cur-
rent recommendation to obtain duplicate scans on old and new
machines within 60 days.(20) To determine if this affected our
Fig. 2. Visual representation of analyses. Analyses included 1559women
from whom there a total of 3618 follow-up visits (starting from the first
follow-up visit to the last follow-up before the clinical diagnosis of post-
menopause could be made). (A) The first set of analyses examined
whether singlemeasures of E2 or FSH could predict imminentMT-related
bone loss. The primary predictors were E2 or FSH (tested in separate
models) measured at each follow-up visit N. The dependent variable
was significant bone loss (categorical outcome, yes versus no) from
SWAN baseline to follow-up visit N + 1. Significant bone loss was defined
as an annualized rate of decrease in BMD that was greater than the
site-specific (LS versus FN) least specific change. (B) The second set of
analyses examined whether within-individual change in E2 or FSH could
predict imminent MT-related bone loss. The primary predictors were
within individual change in E2 or FSH (tested in separate models) from
SWAN baseline to each follow-up visit N. The dependent variable was
significant bone loss (categorical outcome, yes versus no) from SWAN
baseline to follow-up visit N + 1.
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findings, we excluded the 56 of 3618 (approximately 1.5%)
observations that occurred after the Pittsburgh and Oakland
machine upgrades. Third, SWAN’s DXA precision estimates did
not meet the ISCD’s current recommendation to obtain triplicate
or duplicate scans in 15 or 30 subjects.(20) We thus conducted
sensitivity analyses using the ISCD’s limit of acceptable LSC
thresholds (5.3% at the LS and 6.9% at the FN) as alternative def-
initions for significant bone loss.
Results
Participant characteristics: study baseline
This study included 1559 SWAN participants. Half were white,
25% black, 11% Chinese, and 14% Japanese. At study baseline,
58% were premenopausal, and 42% were in early perimeno-
pause. Mean BMD values at the LS and FN were 1.071 and
0.837 g/cm2, respectively. E2 and FSH had skewed distributions,
with median E2 being 52.5 pg/mL (interquartile range [IQR]
32.8–82.1) and median FSH being 15.1 mIU/mL (IQR 11.1–23.3)
(Table 1).
Participant characteristics: repeated measures
Among the 1559 participants, a total of 3618 follow-up visits
after SWAN baseline and before the first postmenopausal visit
(defined as ≥1 year after the FMP) were included in our analyses.
Eleven percent of these follow-up visits occurred during preme-
nopause, 75% in early perimenopause, and 14% in late perimen-
opause. Median E2 was similar during pre- (40.1 pg/mL) and
early perimenopause (44.9 pg/mL) but was significantly lower
in late perimenopause (21.7 pg/mL) (p < 0.001 for comparison
of late perimenopause versus pre- or early perimenopause).
Analogously, median FSH was similar in pre- (15.5 mIU/mL) and
early perimenopause (18.9 mIU/mL) but was significantly higher
in late perimenopause (83.6 mIU/mL) (p < 0.001 for comparison
of late perimenopause versus pre- or early perimenopause)
(Table 2).
BMD decreased at a higher rate in early perimenopause (0.9%
per year [LS]; 0.7% per year [FN]) compared with premenopause
(0.4%per year [LS]; 0.4%per year [FN]) (p < 0.001), and in late peri-
menopause (1.5% per year [LS]; 1.3% per year [FN]) compared
with early perimenopause (p < 0.001). As a consequence, the pro-
portion of observations that were associated with significant
bone loss was lowest in premenopause and greatest in late peri-
menopause (Table 2). The risk of imminent bone loss at the LS
was 2.1-fold greater in early peri- versus premenopausal women
(risk ratio [RR] 2.1, p = 0.008), after accounting for clinical covari-
ates (age, BMI, race/ethnicity, and SWAN study site). Similarly, risk
of imminent bone loss at the LS and FNwas 2.1-fold greater in late
peri- versus early perimenopausal women (risk ratio [RR] 2.1,
p < 0.0001).
Single measure of E2 or FSH as predictor of imminent
bone loss
In repeated measures modified Poisson regression, after adjust-
ing for MT stage (pre- versus early peri- versus late perimeno-
pause) and clinical covariates (age, BMI [at the time of E2
measurement], race/ethnicity, SWAN study site, and whether
E2 was measured during the EFP of the menstrual cycle), lower
E2was associatedwith greater risk of imminent bone loss at both
the LS and FN. With each 50% decrement in E2, risk of significant
bone loss was 10% and 12%greater at the LS (p < 0.0001) and FN
(p = 0.01), respectively. The ability of E2 (combinedwithMT stage
and clinical covariates) to identify women with imminent bone
loss, as assessed by the model AUC, was 0.756 for the LS (com-
pared with 0.752 for MT stage and clinical covariates alone,
p = 0.07) and 0.740 for the FN (compared with 0.735 for MT stage
and clinical covariates alone, p = 0.01) (Table 3).
Higher FSH was also associated with greater risk of imminent
bone loss at both the LS and FN, adjusted for the same covari-
ates. For each twofold increment in FSH, risk of significant bone
loss at the LS and FN was 39% and 27% greater (p < 0.0001 for
both sites), respectively. When combined with MT stage and clin-
ical covariates, the ability of FSH to identify women with immi-
nent bone loss (as assessed by AUC) was 0.782 (p < 0.0001
compared with MT stage and clinical covariates alone) at the
LS and 0.751 (p = 0.02 compared with MT stage and clinical cov-
ariates alone) at the FN (Table 3).
Within-woman change in E2 or FSH as predictor of
imminent bone loss
Greater within-individual declines in E2 and greater increases in
FSH were associated with greater risk of imminent bone loss at
the LS, but not the FN, after adjusting for MT stage (pre- versus
early peri- versus late perimenopause) and clinical covariates.
Similarly, the AUCs for the hormone-plus-covariates models
were significantly higher than the AUCs for the covariates-only
models for the LS but not the FN (Table 3).
Single measure of FSH as predictors of imminent bone
loss, stratified analyses
Because identification of women with significant bone loss was
greatest for single measures of FSH (ie, the model AUC was
Table 1. Descriptive Statistics for Analytic Sample at Study Base-
line: Study of Women’s Health across the Nation (SWAN)
Descriptive
statistic, N = 15591






Body mass index (kg/m2)2 27.2 (7.8)
Menopause transition stage3
Premenopause 907 (58%)
Early perimenopause 652 (42%)
Hormone predictors4





Lumbar spine (g/cm2) 1.071 (0.1)
Femoral neck (g/cm2) 0.837 (0.1)
1 All participants were pre- or early perimenopausal at SWAN baseline.
2 Continuous variables with normal distributions expressed as mean
(standard deviation).
3 Categorical variables expressed as count (proportion).
4 Continuous variables with skewed distributions expressed as median
(interquartile range).
Journal of Bone and Mineral Research E2 AND FSH AS PREDICTORS OF MT-RELATED BONE LOSS 2249 n
greatest) and obtaining single measures of FSH is more practical
than checking within-individual change E2 or FSH, our remaining
analyses focused on one-time measures of FSH. We further char-
acterized the association of FSH with imminent bone loss by
examining whether the association was modified by race/ethni-
city, MT stage, or timing of hormone measurements within the
menstrual cycle. Formal interaction testing confirmed that the
ability of FSH to predict significant bone loss was similar during
pre- and early perimenopause (interaction p = 0.8 [LS]; interac-
tion p = 0.4 [FN]) but was different between early perimenopause
versus late perimenopause (interaction p = 0.03 [LS]; interaction
p = 0.04 [FN]). FSH prediction was not modified by race/ethnicity
or whether the hormone level wasmeasured during the early fol-
licular phase of the menstrual cycle.
In analyses stratified by MT stage (pre- and early perimeno-
pause in one stratum, late postmenopause in a second stratum),
predictions were better earlier in the MT. During pre- and early
perimenopause (stratum 1), each twofold increment in FSH was
associated with 45% and 22% greater risk of significant bone loss
at the LS (p < 0.001) and FN (p = 0.01), respectively, after account-
ing for MT stage (pre- versus early perimenopause) and clinical
covariates. The AUC for FSH plus MT stage and clinical covariates
to predict bone loss at the LS was 0.777 (compared with 0.732 for
MT stage and clinical covariates alone, p < 0.0001) and 0.732 at
Table 2. Descriptive Statistics for Analytic Sample Across All Follow-Up Visits by Menopause Transition Stage1: Study of Women’s Health
Across the Nation (SWAN)
No. of observations2 Premenopause n = 399 Early perimenopause n = 2715 Late perimenopause n = 504
Age (years)3 48.3 (2.4) 48.6 (2.9) 51.8 (2.4)
Body mass index (kg/m2)3 26.7 (6.6) 27.2 (6.6) 28.1 (7.1)
Absolute level of hormone level at follow-up visit N4
Estradiol (pg/mL) 40.1 (25.6, 66.5) 44.9 (26.6, 88.3) 21.7 (13.7, 55.3)
Follicle-stimulating hormone (mIU/mL) 15.5 (12.1, 24.0) 18.9 (12.0, 36.0) 83.6 (50.6, 114.0)
Change in hormone level from SWAN baseline to follow-up visit N4
Estradiol (pg/mL) −7.9 (−28.4, +7.8) −4.9 (−29.5, +27.1) −18.9 (−61.3, +0.4)
Follicle-stimulating hormone (mIU/mL) +2.8 (−1.2, +9.0) +4.3 (−1.8, +19.5) +58.5 (+23.8, +90.5)
Annualized change in bone mineral density from SWAN baseline to follow-up visit N+13
Lumbar spine (g/cm2*year) −0.4 (1.4) −0.9 (1.4) −1.5 (1.5)
Femoral neck (g/cm2*year) −0.4 (1.3) −0.7 (1.4) −1.3 (1.4)
Significant bone loss (yes versus no) from SWAN baseline to follow-up visit N+15
Lumbar spine 15 (3.8%) 312 (11.6%) 190 (38.4%)
Femoral neck 8 (2.0%) 121 (4.5%) 50 (10.1%)
1 All follow-up visits after SWAN baseline for each participant transitioned to postmenopause.
2 Number of visits across all participants in each menopause transition stage.
3 Continuous variables with normal distributions expressed as mean (standard deviation).
4 Continuous variables with skewed distributions expressed as median (interquartile range).
5 Categorical variables expressed as count (percentage).
Table 3. Associations of Estradiol (E2) and Follicle-Stimulating Hormone (FSH), Single Measures, and Within-Woman Change, With Sig-
nificant Bone Loss by the Next Year1
Relative risk (RR) of significant bone loss by the next year (per 50% decrement [halving] of E2, per 100%
increment [doubling] of FSH)
Lumbar spine Femoral neck
RR (95% CI) p Value2 AUC p Value3 RR (95% CI) p Value2 AUC p Value3
Single measures
E2 1.10 (1.06, 1.15) <0.0001 0.756 0.07 1.12 (1.02, 1.23) 0.01 0.740 0.1
FSH 1.39 (1.30, 1.49) <0.0001 0.782 <0.0001 1.27 (1.11, 1.44) <0.001 0.751 0.02
Within-individual change
E2 1.09 (1.04, 1.12) <0.0001 0.759 0.04 1.09 (1.00, 1.19) 0.05 0.745 0.1
FSH 1.17 (1.10, 1.24) <0.0001 0.757 0.04 1.06 (0.94, 1.19) 0.3 0.739 0.8
Covariates only model N/A N/A 0.752 N/A N/A N/A 0.735 N/A
1 Associations estimated using modified Poisson regression on repeated measures from all follow-up visits up to the last visit before postmenopause
(1 year after the FMP). Separate models were run for each hormone predictor level and within-woman change. Bone loss considered significant if
decrease in bone mineral density (from SWAN baseline to the follow-up visit around 1 year after the hormone measurement) was greater than the
site-specific least significant change (3.9% for the lumbar spine and 6.2% for the femoral neck). All models included the following covariates: meno-
pause transition stage, age (years), race/ethnicity, clinical site, body mass index (kg/cm2), and whether samples were collected during the early follic-
ular phase of themenstrual cycle (yes/no). The area under the receiver operator curves (AUC) for eachmodel was estimated using logistic regression to
assess the model’s ability to discriminate between women who were more versus less likely to have significant bone loss in the next year.
2 For hormone predictor.
3 For AUC of model containing hormone predictor with covariates compared with model with covariates only.
Journal of Bone and Mineral Researchn 2250 SHIEH ET AL.
the FN (compared with 0.732 for MT stage and clinical covariates
alone, p = 0.8) (Table 4). During late perimenopause (stratum 2),
each twofold increment in FSH was associated with 21% and
71% greater risk of significant bone loss at the LS (p = 0.001)
and FN (p = 0.001), respectively. As in pre- and early perimeno-
pause, discrimination for imminent bone loss was greater with
FSH plus MT stage and covariates compared with MT stage and
covariates alone at the LS (AUC 0.725 versus 0.642, p < 0.0001)
but not the FN (AUC 0.621 versus 0.603, p = 0.4) (Table 4).
Table 5 reports the sensitivity and specificity of various FSH
thresholds for imminent bone loss.
Sensitivity analyses
We performed three sets of sensitivity analyses. First, we
excluded observations for which change in weight from SWAN
baseline to the exposure follow-up visit was in the bottom 5%
or top 5% of the population distribution. Second, we excluded
observations that occurred after the DXA machine upgrade at
the Pittsburgh and Oakland sites. Third, we used the ISCD’s limit
of acceptable LSC thresholds at the LS or FN as alternative defini-
tions for significant bone loss. For each set of sensitivity analyses,
the associations of E2 and FSH with significant bone loss were
similar to the primary analyses in both unstratified and stratified
models (data not shown).
Discussion
This study had two objectives. The first was to determine if E2 or
FSH, measured once early in the MT, could predict if there will be
significant MT-related bone loss by the next year. The second
was to determine if within-individual change in E2 or FSH was
superior at this prediction compared with one-time measures
of these hormones. We report that single measures of both E2
and FSH predict imminent bone loss by the next year at the LS
and FN, independent of MT stage and clinical covariates. When
combined with these covariates, FSH was better than E2 at iden-
tifying women who were more versus less likely to begin losing
Table 4. Associations of FSH with Significant Bone Loss1 by the Next Year; Stratified by Menopause Transition (MT) Stage
Relative risk (RR) of significant bone loss by the next year (per twofold increment of FSH)
Lumbar spine Femoral neck
MT stage RR (95% CI) p Value2 AUC p Value3 RR (95% CI) p Value2 AUC p Value3
Pre- and early perimenopause
FSH 1.46 (1.34, 1.59) <0.0001 0.777 <0.0001 1.22 (1.04, 1.43) 0.01 0.732 0.8
Covariates only model N/A N/A 0.732 N/A N/A N/A 0.732 N/A
Late perimenopause
FSH 1.21 (1.09, 1.36) 0.001 0.725 <0.0001 1.71 (1.23, 2.37) 0.001 0.621 0.4
Covariates only model N/A N/A 0.642 N/A N/A N/A 0.603 N/A
1 Associations estimated using modified Poisson regression on repeated measures from all follow-up visits up to the last visit before postmenopause
(1 year after the FMP). Bone loss considered significant if decrease in bone mineral density (from SWAN baseline to the follow-up visit around 1 year
after FSH measurement) was greater than the site-specific least significant change (3.9% for the lumbar spine and 6.2% for the femoral neck). All
models included the following covariates: age (years), race/ethnicity, clinical site, body mass index (kg/cm2). In the pre- and early perimenopause stra-
tum, models also included a flag for pre- versus early perimenopause and a flag for whether samples were collected during the early follicular phase of
the menstrual cycle (yes/no). The area under the receiver operator curves (AUC) for each model was estimated using logistic regression to assess the
model’s ability to discriminate between women who were more versus less likely to have significant bone loss in the next year.
2 For hormone predictor.
3 For AUC of model containing hormone predictor with covariates compared tomodel with covariates only (all comparisons made within eachMT stage
stratum).
Table 5. Sensitivity and Specificity of Various FSH Thresholds for Significant Bone Loss by the Next Year
Sensitivity and specificity1 of various FSH thresholds for significant bone loss by the next year
Pre- and early
perimenopause
Lumbar spine Femoral neck
Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI)
FSH ≥8 mIU/mL 97.8 (95.7, 99.0) 3.6 (3.0, 4.3) 96.8 (92.6, 98.9) 3.5 (2.9, 4.2)
FSH ≥16 mIU/mL 77.0 (72.3, 81.2) 46.9 (45.1, 48.6) 66.9 (58.9, 74.2) 45.1 (43.3, 46.8)
FSH ≥32 mIU/mL 45.2 (40.0, 50.5) 83.4 (82.0, 84.7) 31.2 (24.0, 39.1) 81.0 (79.6, 82.3)
FSH ≥64 mIU/mL 16.7 (13.0, 20.9) 96.8 (96.2, 97.4) 11.0 (6.6, 17.1) 95.7 (94.9, 96.4)
Late perimenopause
Lumbar spine Femoral neck
Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI)
FSH ≥8 mIU/mL 100.0 (98.1, 100.0) 2.3 (0.9, 4.7) 100.0 (92.9, 100.0) 1.6 (0.6, 3.2)
FSH ≥16 mIU/mL 95.8 (91.9, 98.2) 11.5 (8.1, 15.6) 98.0 (89.4, 99.9) 9.5 (6.9, 12.6)
FSH ≥32 mIU/mL 88.9 (83.6, 93.0) 30.5 (25.4, 36.0) 86.0 (73.3, 94.2) 24.1 (20.2, 28.4)
FSH ≥64 mIU/mL 41.6 (34.5, 48.9) 72.1 (66.7, 77.1) 52.0 (37.4, 66.3) 69.1 (64.6, 73.4)
1 Sensitivity and specificity reported as %.
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significant bone, based on the AUC metric. Tracking within-
individual change in E2 and FSH did not afford superior predic-
tion of significant bone loss by the following year.
Plausibly, FSH may offer superior prediction of significant
bone loss because it is a better marker of average estrogen-
mediated bioactivity than is E2.(21) Although osteoclasts and
osteoblasts are target cells of E2,(22–26) circulating E2 levels may
not accurately reflect the amount of E2 that enters these cells
to carry out its biological function. In contrast, FSH is produced
by the anterior pituitary gland under feedback inhibition by E2.
The amount of circulating FSH is thus a direct reflection of
E2-mediated bioactivity at the level of the target cell (ie, the pitu-
itary). This rationale is analogous to why thyroid stimulating hor-
mone (TSH) is considered a better marker of thyroid hormone
status than either thyroxine (T4) or triiodothyronine (T3).(27) Add-
ing FSH to clinical covariates increases the AUC for predicting
bone loss by the next year at the LS (from 0.732 to 0.777 in
pre- and early perimenopause and from 0.642 to 0.725 in late
perimenopause).
Our second main finding was that tracking within-individual
change in E2 or FSH was not better than using single measures
of these hormones for identifying women who were more likely
to lose significant BMDby the next year. We hypothesize that this
is attributable to unavoidable measurement error. Because E2
and FSH values fluctuate markedly throughout the menstrual
cycle, serial measures of these hormones should be obtained at
the same point in the menstrual cycle.(15,28) This becomes less
feasible as menstrual cycles became increasingly irregular in
perimenopause. In fact, whereas 100% of SWAN visits in preme-
nopause occurred during the EFP (dates 2 to 5 of the menstrual
cycle), only 57% and 6% of visits in early peri- and late perimen-
opause, respectively, occurred during the EFP.
Our third key finding is that one-timemeasures of both E2 and
FSH were stronger predictors of significant bone loss by the next
year at the LS than at the FN. We suspect that this is attributable
to the lesser BMD decline at the FN site during the MT, com-
pounded by the larger CV of FN BMDmeasures. In our study sam-
ple, the mean annual rate of decline in FN BMD during late
perimenopause (when MT-related decline is fastest) was lower
than the SWAN CV.
Strengths of this study include its multiracial/ethnic composi-
tion; longitudinal study design with repeated measures of BMD,
E2, and FSH; and careful documentation of the FMP. However,
our study has several limitations that warrant mention. First,
although we tried to collect serum samples during the EFP of
the menstrual cycle, this was not always possible, especially in
the late perimenopausal visits. Because E2 and FSH values vary
markedly during the menstrual cycle, tracking within-individual
change in measurements obtained at different time points intro-
duces measurement error. Second, SWAN protocols (initiated
~20 years ago) for computing cross-calibrations after a DXA hard-
ware change and for calculating the in vivo precision error of DXA
scans do not meet the current ISCD recommendations.(20) To
address this, we conducted sensitivity analyses that: 1) excluded
the 56 of 3618 observations that occurred after the machine
changes at the Pittsburgh and Oakland sites; and 2) used the
ISCD’s limit of acceptable LSC thresholds at the LS or FN as alter-
native thresholds for significant bone loss. Results from sensitivity
analyses were essentially unchanged from primary analyses.
Third, although many studies suggest that BMD decline, at rates
commonly observed during the MT,(1) is a risk factor for
fracture(5–9,29–31) and fast BMD decline in midlife is associated
with appendicular and vertebral fractures,(8,9,31) the relative
contributions of peak bone mass versus BMD loss to fracture risk
have not been established. For example, the risk associated with
BMD loss may depend on starting BMD(30) and fracture site (eg,
vertebral versus hip),(32) but at least one study reported that peak
bone mass and BMD loss are equally important.(31)
In conclusion, both lower E2 and greater FSH values, mea-
sured once during pre- or perimenopause, were associated with
greater risk of imminent bone loss, independent of relevant clin-
ical risk factors, especially at the LS. However, FSH was better
than E2 at identifying women who were more likely to lose sig-
nificant BMD by next year, and tracking within-individual change
in E2 or FSH was not better than using one-time measures.
Future studies will test FSH in combination with clinical covari-
ates and other biomarkers (eg, anti-Mullerian hormone or bone
turnover markers) to develop models that can prospectively
identify womenwho are about to begin losing bone. This, in turn,
will enable us to test whether early, time-limited interventions
can prevent MT-related bone loss and ultimately whether this
reduces the risk of future fracture.
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